Cargando…

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Hui, Wang, Xing, Li, Jiao, Ye, Yingying, Wang, Dedao, Fang, Wei, Mi, Lan, Ding, Ning, Wang, Xiaogan, Song, Yuqin, Zhu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082047/ https://www.ncbi.nlm.nih.gov/pubmed/33981831 http://dx.doi.org/10.1016/j.omto.2021.03.015

Ejemplares similares

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen
por: Yu, Hui, et al.
Publicado: (2022)

The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma
por: Li, Jiao, et al.
Publicado: (2022)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

P1165: PRELIMINARY FINDINGS OF A PHASE Ⅱ STUDY OF CHEMO-FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH-DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
por: Zhang, Yan, et al.
Publicado: (2023)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Development of a UPLC-MS/MS method for the determination of orelabrutinib in rat plasma and its application in pharmacokinetics
por: Liu, Ya-nan, et al.
Publicado: (2022)

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
por: Ding, Ning, et al.
Publicado: (2015)

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS
por: Sun, Lu-Ning, et al.
Publicado: (2023)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis
por: Li, Yufeng, et al.
Publicado: (2023)

Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
por: Qiao, Lijiao, et al.
Publicado: (2023)

BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report
por: Feng, Lan, et al.
Publicado: (2022)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
por: Shi, Cunzhen, et al.
Publicado: (2018)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017)

Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
por: Yang, Chuanwei, et al.
Publicado: (2022)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
por: Li, Miaomiao, et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS
por: Wang, Haitao, et al.
Publicado: (2023)

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
por: Deng, Li-Juan, et al.
Publicado: (2023)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas
por: Ye, Yingying, et al.
Publicado: (2021)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors
por: Gao, Hongye, et al.
Publicado: (2023)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY
por: Shi, Yan, et al.
Publicado: (2023)

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
por: Zhang, Jing, et al.
Publicado: (2022)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
por: Liu, Jiaxin, et al.
Publicado: (2023)

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
por: Wang, Sicong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5ia63upa9bfhlpieltu550kh30